SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Prescription Drugs

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2169370

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2169370

Obesity GLP-1 Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 280 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 7295
Printable PDF & Excel (Enterprise License above 5 users)
USD 8495

Add to Cart

Description

Table of Contents

Introduction

GLP-1 receptor agonists have transformed obesity care, offering patients and physicians a medical option that delivers substantial and sustained weight loss alongside improvements in blood sugar, blood pressure and cardiovascular risk. Originally developed for type 2 diabetes, these medicines now sit at the center of a fast-moving obesity treatment market. In 2026, the market is valued at US$27.5 Bn and is projected to reach US$65.2 Bn by 2033, registering a CAGR of 13.10%. This momentum is built on the rising global prevalence of obesity, strong clinical results and a widening list of approved uses beyond weight reduction alone. The market is also changing quickly in structure. Oral formulations are arriving to complement weekly injections, cash prices are falling, and next-generation molecules that act on two or three hormone pathways are moving through development. Generic versions are beginning to enter several countries, while online pharmacies and telehealth services are making it easier for patients to obtain prescriptions and maintain long-term treatment.

Market Insights

The market is segmented by drug, route of administration and distribution channel. Drugs include semaglutide, tirzepatide, liraglutide, and orforglipron and other agents, reflecting both established therapies and newer entrants. By route of administration, products are available as injectable and oral formulations. Distribution channels cover retail pharmacies, hospital pharmacies, and online and mail-order pharmacies. Several clear trends are shaping the market. Oral pills are gaining attention because they remove the need for injections and may suit patients who are reluctant to self-inject. Lower cash prices are broadening access for people without full insurance coverage. Developers are advancing next-generation dual and triple agonists that target additional hormone pathways to achieve greater weight loss and metabolic benefit. Generic semaglutide is entering India, China, Canada and Brazil, introducing more affordable options in those countries. Meanwhile, online and telehealth channels are growing rapidly, connecting patients with prescribers and providing convenient home delivery and ongoing support throughout treatment.

Drivers

The primary driver is the rising prevalence of obesity combined with the strong efficacy of GLP-1 therapies, an influence with high impact over the long term. Obesity rates continue to climb across both developed and developing countries, and clinical data showing meaningful, durable weight reduction have encouraged physicians to prescribe these medicines more widely. The second driver is expansion of approved indications and reimbursement, carrying high impact in the medium term, particularly in North America and Europe. As evidence supports benefits in cardiovascular, kidney and other related conditions, payers are more willing to cover treatment, bringing more patients into therapy. Restraints remain important context. High costs and pricing pressure form a high-impact, short-term restraint, as list prices strain budgets and governments and insurers push for discounts. Side effects and treatment discontinuation create a medium-impact, medium-term challenge, since gastrointestinal effects lead some patients to stop therapy, and weight regain after stopping raises questions about long-term adherence and value.

Business Opportunity

Oral and next-generation agonists open a high-growth revenue pool. Pills offer a convenient alternative to injections and can be easier to manufacture and distribute at scale, which may support broader use in primary care. Dual and triple agonists that act on several hormone pathways promise greater weight loss and wider metabolic benefits, giving developers a route to differentiate their products as competition intensifies. Companies that bring well-tolerated, effective new agents to market can capture strong demand from both new patients and those switching therapy. Asia Pacific and emerging markets create a second, volume-oriented revenue pool. Large populations, rising obesity rates and increasing health awareness point to significant untreated demand. The launch of generic semaglutide in India in March 2026 shows how lower-cost options can quickly widen access in price-sensitive countries. Suppliers that pair affordable pricing with local manufacturing, distribution partnerships and digital prescribing channels can build substantial patient bases, balancing premium innovation with high-volume growth through 2033.

Region Analysis

North America leads the market with a 76.5% share in 2026. High obesity prevalence, broad physician familiarity with GLP-1 therapies, expanding reimbursement and fast growth in telehealth prescribing support the region's dominant position, even as pricing pressure from payers increases. Europe is another important market, where expanding approved indications and gradually improving reimbursement are bringing more patients into treatment, although national cost controls shape access and uptake. Asia Pacific is the fastest-growing region, advancing at an 18.8% CAGR through 2033. Rising obesity rates, growing awareness of medical weight management and the arrival of generic semaglutide in markets such as India and China are opening access to large populations. Latin America shows rising demand, with generic semaglutide entering Brazil and private healthcare providers offering weight management programs. The Middle East and Africa form a smaller market, but high obesity rates in several Gulf countries and growing private healthcare investment are creating meaningful interest in GLP-1 based treatment across the region.

Key Players

  • Novo Nordisk
  • Eli Lilly
  • Pfizer
  • Amgen
  • Roche
  • AstraZeneca
  • Boehringer Ingelheim
  • Zealand Pharma
  • Viking Therapeutics
  • Structure Therapeutics

Segmentation

By Drug:

  • Semaglutide
  • Tirzepatide
  • Liraglutide
  • Orforglipron & Others

By Route of Administration:

  • Injectable
  • Oral

By Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online & Mail-Order Pharmacies

By Geographic Coverage:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Obesity GLP-1 Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Obesity GLP-1 Market Outlook, 2020 - 2033

  • 3.1. Global Obesity GLP-1 Market Outlook, by Drug, Value (US$ Bn), 2020-2033
    • 3.1.1. Semaglutide
    • 3.1.2. Tirzepatide
    • 3.1.3. Liraglutide
    • 3.1.4. Orforglipron & Others
  • 3.2. Global Obesity GLP-1 Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 3.2.1. Injectable
    • 3.2.2. Oral
  • 3.3. Global Obesity GLP-1 Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 3.3.1. Retail Pharmacies
    • 3.3.2. Hospital Pharmacies
    • 3.3.3. Online & Mail-Order Pharmacies
  • 3.4. Global Obesity GLP-1 Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Obesity GLP-1 Market Outlook, 2020 - 2033

  • 4.1. North America Obesity GLP-1 Market Outlook, by Drug, Value (US$ Bn), 2020-2033
    • 4.1.1. Semaglutide
    • 4.1.2. Tirzepatide
    • 4.1.3. Liraglutide
    • 4.1.4. Orforglipron & Others
  • 4.2. North America Obesity GLP-1 Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 4.2.1. Injectable
    • 4.2.2. Oral
  • 4.3. North America Obesity GLP-1 Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 4.3.1. Retail Pharmacies
    • 4.3.2. Hospital Pharmacies
    • 4.3.3. Online & Mail-Order Pharmacies
  • 4.4. North America Obesity GLP-1 Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 4.4.2. U.S. Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 4.4.3. U.S. Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 4.4.4. Canada Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 4.4.5. Canada Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 4.4.6. Canada Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Obesity GLP-1 Market Outlook, 2020 - 2033

  • 5.1. Europe Obesity GLP-1 Market Outlook, by Drug, Value (US$ Bn), 2020-2033
    • 5.1.1. Semaglutide
    • 5.1.2. Tirzepatide
    • 5.1.3. Liraglutide
    • 5.1.4. Orforglipron & Others
  • 5.2. Europe Obesity GLP-1 Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 5.2.1. Injectable
    • 5.2.2. Oral
  • 5.3. Europe Obesity GLP-1 Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 5.3.1. Retail Pharmacies
    • 5.3.2. Hospital Pharmacies
    • 5.3.3. Online & Mail-Order Pharmacies
  • 5.4. Europe Obesity GLP-1 Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 5.4.2. Germany Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 5.4.3. Germany Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.4. Italy Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 5.4.5. Italy Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 5.4.6. Italy Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.7. France Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 5.4.8. France Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 5.4.9. France Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.10. U.K. Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 5.4.11. U.K. Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 5.4.12. U.K. Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.13. Spain Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 5.4.14. Spain Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 5.4.15. Spain Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.16. Russia Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 5.4.17. Russia Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 5.4.18. Russia Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.19. Rest of Europe Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 5.4.20. Rest of Europe Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 5.4.21. Rest of Europe Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Obesity GLP-1 Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Obesity GLP-1 Market Outlook, by Drug, Value (US$ Bn), 2020-2033
    • 6.1.1. Semaglutide
    • 6.1.2. Tirzepatide
    • 6.1.3. Liraglutide
    • 6.1.4. Orforglipron & Others
  • 6.2. Asia Pacific Obesity GLP-1 Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 6.2.1. Injectable
    • 6.2.2. Oral
  • 6.3. Asia Pacific Obesity GLP-1 Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 6.3.1. Retail Pharmacies
    • 6.3.2. Hospital Pharmacies
    • 6.3.3. Online & Mail-Order Pharmacies
  • 6.4. Asia Pacific Obesity GLP-1 Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 6.4.2. China Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 6.4.3. China Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.4. Japan Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 6.4.5. Japan Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 6.4.6. Japan Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.7. South Korea Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 6.4.8. South Korea Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 6.4.9. South Korea Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.10. India Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 6.4.11. India Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 6.4.12. India Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.13. Southeast Asia Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 6.4.14. Southeast Asia Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 6.4.15. Southeast Asia Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.16. Rest of SAO Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 6.4.17. Rest of SAO Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 6.4.18. Rest of SAO Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Obesity GLP-1 Market Outlook, 2020 - 2033

  • 7.1. Latin America Obesity GLP-1 Market Outlook, by Drug, Value (US$ Bn), 2020-2033
    • 7.1.1. Semaglutide
    • 7.1.2. Tirzepatide
    • 7.1.3. Liraglutide
    • 7.1.4. Orforglipron & Others
  • 7.2. Latin America Obesity GLP-1 Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 7.2.1. Injectable
    • 7.2.2. Oral
  • 7.3. Latin America Obesity GLP-1 Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 7.3.1. Retail Pharmacies
    • 7.3.2. Hospital Pharmacies
    • 7.3.3. Online & Mail-Order Pharmacies
  • 7.4. Latin America Obesity GLP-1 Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 7.4.2. Brazil Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 7.4.3. Brazil Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.4. Mexico Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 7.4.5. Mexico Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 7.4.6. Mexico Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.7. Argentina Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 7.4.8. Argentina Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 7.4.9. Argentina Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.10. Rest of LATAM Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 7.4.11. Rest of LATAM Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 7.4.12. Rest of LATAM Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Obesity GLP-1 Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Obesity GLP-1 Market Outlook, by Drug, Value (US$ Bn), 2020-2033
    • 8.1.1. Semaglutide
    • 8.1.2. Tirzepatide
    • 8.1.3. Liraglutide
    • 8.1.4. Orforglipron & Others
  • 8.2. Middle East & Africa Obesity GLP-1 Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 8.2.1. Injectable
    • 8.2.2. Oral
  • 8.3. Middle East & Africa Obesity GLP-1 Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 8.3.1. Retail Pharmacies
    • 8.3.2. Hospital Pharmacies
    • 8.3.3. Online & Mail-Order Pharmacies
  • 8.4. Middle East & Africa Obesity GLP-1 Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 8.4.2. GCC Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 8.4.3. GCC Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.4. South Africa Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 8.4.5. South Africa Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 8.4.6. South Africa Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.7. Egypt Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 8.4.8. Egypt Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 8.4.9. Egypt Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.10. Nigeria Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 8.4.11. Nigeria Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 8.4.12. Nigeria Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.13. Rest of Middle East Obesity GLP-1 Market Outlook, by Drug, 2020-2033
    • 8.4.14. Rest of Middle East Obesity GLP-1 Market Outlook, by Route of Administration, 2020-2033
    • 8.4.15. Rest of Middle East Obesity GLP-1 Market Outlook, by Distribution Channel, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Novo Nordisk
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Eli Lilly
    • 9.4.3. Pfizer
    • 9.4.4. Amgen
    • 9.4.5. Roche
    • 9.4.6. AstraZeneca
    • 9.4.7. Boehringer Ingelheim
    • 9.4.8. Zealand Pharma
    • 9.4.9. Viking Therapeutics
    • 9.4.10. Structure Therapeutics

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!